{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:24:52Z","timestamp":1787095492417,"version":"build-2736575974"},"reference-count":280,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2054\/19"],"award-info":[{"award-number":["2054\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013043","name":"Ariel University","doi-asserted-by":"publisher","award":["RA2000000457"],"award-info":[{"award-number":["RA2000000457"]}],"id":[{"id":"10.13039\/501100013043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cyto.2026.157194","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:43:46Z","timestamp":1786344226000},"page":"157194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Translational perspectives of next-generation cytokine therapies for musculoskeletal disorders"],"prefix":"10.1016","volume":"206","author":[{"given":"Alexander","family":"Kalinkovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Livshits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0005","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2471\/BLT.17.204891","article-title":"Reducing the global burden of musculoskeletal conditions","volume":"96","author":"Briggs","year":"2018","journal-title":"Bull World Health Organ."},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb0010","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00198-022-06454-3","article-title":"Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis","volume":"33","author":"Xiao","year":"2022","journal-title":"Osteoporos Int."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0020","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cells11030394","article-title":"Causes of and Molecular Targets for the Treatment of Intervertebral Disc Degeneration: A Review","volume":"11","author":"Ohnishi","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.joca.2022.11.005","article-title":"Pharmaceutical treatment of osteoarthritis","volume":"31","author":"Richard","year":"2023","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.cyto.2026.157194_bb0035","article-title":"Osteoporosis treatment: current drugs and future developments","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2025.106038","article-title":"Nutritional and Pharmacological Interventions for Sarcopenia in Older Adults: A Systematic Review and Network Meta-Analysis","volume":"27","author":"Zhang","year":"2026","journal-title":"J Am Med Dir Assoc."},{"key":"10.1016\/j.cyto.2026.157194_bb0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.arr.2016.09.008","article-title":"Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis","volume":"35","author":"Kalinkovich","year":"2017","journal-title":"Ageing Res Rev."},{"issue":"7","key":"10.1016\/j.cyto.2026.157194_bb0050","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.40504","article-title":"Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis","volume":"70","author":"Falconer","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"15","key":"10.1016\/j.cyto.2026.157194_bb0055","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3390\/cells11152359","article-title":"Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update","volume":"11","author":"Jimenez-Gutierrez","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/BOR.0000000000000923","article-title":"Inflammation in osteoarthritis: the latest progress and ongoing challenges","volume":"35","author":"Knights","year":"2023","journal-title":"Curr Opin Rheumatol."},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb0065","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1007\/s00586-023-07717-1","article-title":"The importance of inflammatory biomarkers in non-specific acute and chronic low back pain: a systematic review","volume":"32","author":"Pinto","year":"2023","journal-title":"Eur Spine J."},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb0070","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.cyto.2026.157194_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2025.102187","article-title":"Clinical application of biological agents in rheumatoid arthritis","volume":"89","author":"Cheng","year":"2025","journal-title":"Transpl Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102552","article-title":"Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers","volume":"36","author":"Chen","year":"2025","journal-title":"Mol Ther Nucleic Acids."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0085","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3390\/ph18111612","article-title":"Targeting Inflammatory Pathways in Chronic Low Back Pain: Opportunities for Novel Therapeutics","volume":"18","author":"Anyfanti","year":"2025","journal-title":"Pharmaceuticals (Basel)."},{"issue":"15","key":"10.1016\/j.cyto.2026.157194_bb0090","article-title":"Cytokines: From Clinical Significance to Quantification","volume":"8","author":"Liu","year":"2021","journal-title":"Adv Sci (Weinh)."},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.41585","article-title":"Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models","volume":"73","author":"Yuba","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2026.157194_bb0100","article-title":"The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis","volume":"13","author":"Mukherjee","year":"2024","journal-title":"Biomater Biosyst."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0105","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/s41598-023-27981-x","article-title":"Local IL-10 delivery modulates the immune response and enhances repair of volumetric muscle loss muscle injury","volume":"13","author":"Huynh","year":"2023","journal-title":"Sci Rep."},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/jir.2018.0089","article-title":"Interleukin 30 to Interleukin 40","volume":"38","author":"Catalan-Dibene","year":"2018","journal-title":"J Interferon Cytokine Res."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0115","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3390\/ijms20061257","article-title":"IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential","volume":"20","author":"Boutet","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5114\/ceji.2020.97911","article-title":"Interleukin 39: a new member of interleukin 12 family","volume":"45","author":"Lu","year":"2020","journal-title":"Cent Eur J Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156348","article-title":"Role of IL-34 and its receptors in inflammatory diseases","volume":"171","author":"Shang","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2026.157194_bb0130","first-page":"3968767","article-title":"A Comprehensive Review on the Role of Interleukin-40 as a Biomarker for Diagnosing Inflammatory Diseases","volume":"2024","author":"Dabbagh-Gorjani","year":"2024","journal-title":"Autoimmune Dis."},{"issue":"54","key":"10.1016\/j.cyto.2026.157194_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax1686","article-title":"Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine","volume":"5","author":"Hovhannisyan","year":"2020","journal-title":"Sci Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jir.2021.0147","article-title":"Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases","volume":"41","author":"Ye","year":"2021","journal-title":"J Interferon Cytokine Res."},{"issue":"19","key":"10.1016\/j.cyto.2026.157194_bb0145","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.3390\/ijms26199711","article-title":"Emerging Therapeutic and Inflammation Biomarkers: The Role of Meteorin-Like (Metrnl) and Follistatin-Like 1 (FSTL1) in Inflammatory Diseases","volume":"26","author":"Velikova","year":"2025","journal-title":"Int J Mol Sci."},{"issue":"5877","key":"10.1016\/j.cyto.2026.157194_bb0150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.1154370","article-title":"Discovery of a cytokine and its receptor by functional screening of the extracellular proteome","volume":"320","author":"Lin","year":"2008","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb0155","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ni.2360","article-title":"IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia","volume":"13","author":"Wang","year":"2012","journal-title":"Nat Immunol."},{"issue":"12","key":"10.1016\/j.cyto.2026.157194_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081665","article-title":"The newly discovered cytokine IL-34 is expressed in gingival fibroblasts, shows enhanced expression by pro-inflammatory cytokines, and stimulates osteoclast differentiation","volume":"8","author":"Bostr\u00f6m","year":"2013","journal-title":"PLoS One."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0165","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/imm.12660","article-title":"Functions of interleukin-34 and its emerging association with rheumatoid arthritis","volume":"149","author":"Zhou","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.cyto.2026.157194_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156348","article-title":"Role of IL-34 and its receptors in inflammatory diseases","volume":"171","author":"Shang","year":"2023","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0175","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/cas.70020","article-title":"Role of IL-34 in Tumors and Its Application to Regulate Inflammation","volume":"116","author":"Igarashi","year":"2025","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajpath.2016.09.015","article-title":"Bone Morphogenetic Protein 2 and Transforming Growth Factor \u03b21 Inhibit the Expression of the Proinflammatory Cytokine IL-34 in Rheumatoid Arthritis Synovial Fibroblasts","volume":"187","author":"Chemel","year":"2017","journal-title":"Am J Pathol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0185","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/JLB.MR1117-457R","article-title":"Interleukin-34, a comprehensive review","volume":"104","author":"Baghdadi","year":"2018","journal-title":"J Leukoc Biol."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0190","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/JLB.3RU1120-773R","article-title":"IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases","volume":"110","author":"Freuchet","year":"2021","journal-title":"J Leukoc Biol."},{"issue":"30","key":"10.1016\/j.cyto.2026.157194_bb0195","doi-asserted-by":"crossref","first-page":"21972","DOI":"10.1074\/jbc.M112.442731","article-title":"Receptor-type protein-tyrosine phosphatase \u03b6 is a functional receptor for interleukin-34","volume":"288","author":"Nandi","year":"2013","journal-title":"J Biol Chem."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1615\/CritRevImmunol.2023050326","article-title":"Interleukin 34 in Disease Progressions: A Comprehensive Review","volume":"43","author":"Boruah","year":"2023","journal-title":"Crit Rev Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0205","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cyto.2015.05.029","article-title":"IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization","volume":"76","author":"S\u00e9galiny","year":"2015","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0210","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.bbamcr.2015.01.023","article-title":"Syndecan-1 regulates the biological activities of interleukin-34","volume":"1853","author":"Segaliny","year":"2015","journal-title":"Biochim Biophys Acta."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0215","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/art.41792","article-title":"Interleukin-34 Reprograms Glycolytic and Osteoclastic Rheumatoid Arthritis Macrophages via Syndecan 1 and Macrophage Colony-Stimulating Factor Receptor","volume":"73","author":"Van Raemdonck","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2026.157194_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109635","article-title":"Significance of IL-34 and SDC-1 in the pathogenesis of RA cells and preclinical models","volume":"251","author":"Alzoubi","year":"2023","journal-title":"Clin Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0225","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/13872877251320418","article-title":"IL-34\/TREM2 modulates microglia-mediated inflammation and provides neuroprotection in a mouse model of sporadic Alzheimer\u2019s disease","volume":"104","author":"Wang","year":"2025","journal-title":"J Alzheimers Dis."},{"issue":"26","key":"10.1016\/j.cyto.2026.157194_bb0230","first-page":"3184","article-title":"TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice","volume":"141","author":"Xie","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0235","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1189\/jlb.1209822","article-title":"Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells","volume":"88","author":"Wei","year":"2010","journal-title":"J Leukoc Biol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0240","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00774-013-0476-3","article-title":"IL-34 and CSF-1: similarities and differences","volume":"31","author":"Nakamichi","year":"2013","journal-title":"J Bone Miner Metab."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0245","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cbin.10771","article-title":"AG490 suppresses interleukin-34-mediated osteoclastogenesis in mice bone marrow macrophages","volume":"41","author":"Cheng","year":"2017","journal-title":"Cell Biol Int."},{"issue":"7","key":"10.1016\/j.cyto.2026.157194_bb0250","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.7150\/thno.107340","article-title":"Interleukin-34 orchestrates bone formation through its binding to bone morphogenic proteins","volume":"15","author":"Mu\u00f1oz-Garcia","year":"2025","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0255","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00296-010-1688-7","article-title":"Proinflammatory cytokines, IL-1\u03b2 and TNF-\u03b1, induce expression of interleukin-34 mRNA via JNK- and p44\/42 MAPK-NF-\u03baB pathway but not p38 pathway in osteoblasts","volume":"31","author":"Eda","year":"2011","journal-title":"Rheumatol Int."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0260","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3892\/mmr.2014.2353","article-title":"Tumor necrosis factor-\u03b1 induces interleukin-34 expression through nuclear factor-\u03baB activation in MC3T3-E1 osteoblastic cells","volume":"10","author":"Yu","year":"2014","journal-title":"Mol Med Rep."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0265","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.joca.2020.10.013","article-title":"The differentiation of prehypertrophic into hypertrophic chondrocytes drives an OA-remodeling program and IL-34 expression","volume":"29","author":"van Eegher","year":"2021","journal-title":"Osteoarthritis Cartilage."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0270","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11657-023-01343-6","article-title":"Elevated circulating levels of IL-34 are strongly associated with osteoporosis","volume":"18","author":"Tarabeih","year":"2023","journal-title":"Arch Osteoporos."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0275","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3899\/jrheum.130356","article-title":"Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis","volume":"40","author":"Moon","year":"2013","journal-title":"J Rheumatol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/14397595.2019.1593576","article-title":"The correlation between interleukin-34 and bone erosion under ultrasound in rheumatoid arthritis","volume":"30","author":"Li","year":"2020","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.cyto.2026.157194_bb0285","doi-asserted-by":"crossref","first-page":"1078350","DOI":"10.3389\/fmed.2022.1078350","article-title":"Interleukin-34-regulated T-cell responses in rheumatoid arthritis","volume":"9","author":"Park","year":"2022","journal-title":"Front Med (Lausanne)."},{"issue":"7","key":"10.1016\/j.cyto.2026.157194_bb0290","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/jir.2012.0122","article-title":"Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production","volume":"33","author":"Tian","year":"2013","journal-title":"J Interferon Cytokine Res."},{"issue":"7","key":"10.1016\/j.cyto.2026.157194_bb0295","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3899\/jrheum.151253","article-title":"Interleukin 34 Upregulation Contributes to the Increment of MicroRNA 21 Expression through STAT3 Activation Associated with Disease Activity in Rheumatoid Arthritis","volume":"43","author":"Yang","year":"2016","journal-title":"J Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0300","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/jir.2017.0095","article-title":"Interleukin-34 Aggravates the Severity of Arthritis in Collagen-Induced Arthritis Mice by Inducing Interleukin-17 Production","volume":"38","author":"Zhang","year":"2018","journal-title":"J Interferon Cytokine Res."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0305","doi-asserted-by":"crossref","first-page":"20510","DOI":"10.1038\/s41598-020-77510-3","article-title":"The heparan sulfate proteoglycan Syndecan-1 influences local bone cell communication via the RANKL\/OPG axis","volume":"10","author":"Timmen","year":"2020","journal-title":"Sci Rep."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0310","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1684\/ecn.2019.0428","article-title":"Effects of IL-34 on the secretion of RANKL\/OPG by fibroblast-like synoviocytes and peripheral blood mononuclear cells in rheumatoid arthritis","volume":"30","author":"Cui","year":"2019","journal-title":"Eur Cytokine Netw."},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb0315","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41374-022-00772-0","article-title":"IL-34 and protein-tyrosine phosphatase receptor type-zeta-dependent mechanisms limit arthritis in mice","volume":"102","author":"Gonz\u00e1lez-S\u00e1nchez","year":"2022","journal-title":"Lab Invest."},{"key":"10.1016\/j.cyto.2026.157194_bb0320","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2095480","article-title":"Interleukin-34 Synovial Fluid Was Associated with Knee Osteoarthritis Severity: A Cross-Sectional Study in Knee Osteoarthritis Patients in Different Radiographic Stages","author":"Wang","year":"2018","journal-title":"Dis Markers."},{"key":"10.1016\/j.cyto.2026.157194_bb0325","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cytogfr.2019.05.005","article-title":"Interleukin-34 as a promising clinical biomarker and therapeutic target for inflammatory arthritis","volume":"47","author":"Udomsinprasert","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2_suppl","key":"10.1016\/j.cyto.2026.157194_bb0330","doi-asserted-by":"crossref","first-page":"1174S","DOI":"10.1177\/1947603521990866","article-title":"Diagnostic Value of Interleukin-34 as a Novel Biomarker for Severity of Knee Osteoarthritis","volume":"13","author":"Udomsinprasert","year":"2021","journal-title":"Cartilage"},{"issue":"22","key":"10.1016\/j.cyto.2026.157194_bb0335","doi-asserted-by":"crossref","first-page":"11090","DOI":"10.3390\/ijms262211090","article-title":"IL-34 as a Novel Mediator Linking Vitamin D Deficiency with Osteoporosis and Knee Osteoarthritis","volume":"26","author":"Tarabeih","year":"2025","journal-title":"Int J Mol Sci."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0340","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1038\/s41598-020-64932-2","article-title":"Interleukin-34 overexpression mediated through tumor necrosis factor-alpha reflects severity of synovitis in knee osteoarthritis","volume":"10","author":"Udomsinprasert","year":"2020","journal-title":"Sci Rep."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0345","first-page":"89","article-title":"Serum levels of interleukin-34 and RANKL as multivariable predictors of bone erosion seen by ultrasonography in patients with ankylosing spondylitis","volume":"16","author":"Huang","year":"2022","journal-title":"Asian Biomed (Res Rev News)."},{"key":"10.1016\/j.cyto.2026.157194_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.579000","article-title":"Inhibition of IL-34 Unveils Tissue-Selectivity and Is Sufficient to Reduce Microglial Proliferation in a Model of Chronic Neurodegeneration","volume":"11","author":"Obst","year":"2020","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010112","article-title":"New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma","volume":"13","author":"Joalland","year":"2025","journal-title":"J Immunother Cancer."},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb0360","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1471-4906(01)02040-3","article-title":"A new nomenclature for IL-1-family genes","volume":"22","author":"Sims","year":"2001","journal-title":"Trends Immunol."},{"issue":"14","key":"10.1016\/j.cyto.2026.157194_bb0365","doi-asserted-by":"crossref","first-page":"13677","DOI":"10.1074\/jbc.M400117200","article-title":"Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs","volume":"279","author":"Towne","year":"2004","journal-title":"J Biol Chem."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0370","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri2691","article-title":"The IL-1 family: regulators of immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat Rev Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0375","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ni1110-973","article-title":"IL-1 family nomenclature","volume":"11","author":"Dinarello","year":"2010","journal-title":"Nat Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0380","first-page":"7","article-title":"IL-36 a new member of the IL-1 family cytokines","volume":"26","author":"Tripodi","year":"2012","journal-title":"J Biol Regul Homeost Agents."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0385","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144336","article-title":"IL-36 in chronic inflammation and fibrosis - bridging the gap?","volume":"131","author":"Elias","year":"2021","journal-title":"J Clin Invest."},{"issue":"18","key":"10.1016\/j.cyto.2026.157194_bb0390","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.3390\/ijms21186458","article-title":"Interleukin-36 Cytokine\/Receptor Signaling: A New Target for Tissue Fibrosis","volume":"21","author":"Melton","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0395","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imm.13310","article-title":"IL-36 cytokines and gut immunity","volume":"163","author":"Ngo","year":"2021","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0400","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/imr.12610","article-title":"Regulation and function of interleukin-36 cytokines","volume":"281","author":"Bassoy","year":"2018","journal-title":"Immunol Rev."},{"key":"10.1016\/j.cyto.2026.157194_bb0405","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3389\/fimmu.2019.02532","article-title":"Biology of IL-36 Signaling and Its Role in Systemic Inflammatory Diseases","volume":"10","author":"Yuan","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb0410","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/5584_2020_488","article-title":"Interleukin-36: Structure, Signaling and Function","volume":"21","author":"Zhou","year":"2021","journal-title":"Adv Exp Med Biol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0415","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00535-022-01936-x","article-title":"Pro- and anti-inflammatory roles of interleukin (IL)-33, IL-36, and IL-38 in inflammatory bowel disease","volume":"58","author":"Andoh","year":"2023","journal-title":"J Gastroenterol."},{"key":"10.1016\/j.cyto.2026.157194_bb0420","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.2147\/JIR.S474879","article-title":"Role of IL-1 Family Cytokines IL-36, IL-37, IL-38 in Osteoarthritis and Rheumatoid Arthritis: A Comprehensive Review","volume":"17","author":"Xu","year":"2024","journal-title":"J Inflamm Res."},{"key":"10.1016\/j.cyto.2026.157194_bb0425","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cytogfr.2020.06.006","article-title":"IL-36 in chronic inflammation and cancer","volume":"55","author":"Neurath","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0430","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/ijms22010285","article-title":"Role of IL-36 Cytokines in the Regulation of Angiogenesis Potential of Trophoblast Cells","volume":"22","author":"Murrieta-Coxca","year":"2020","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.cyto.2026.157194_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832185","article-title":"Increased Levels of Interleukin-36 in Obesity and Type 2 Diabetes Fuel Adipose Tissue Inflammation by Inducing Its Own Expression and Release by Adipocytes and Macrophages","volume":"13","author":"Fr\u00fchbeck","year":"2022","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0440","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/mi.2017.21","article-title":"IL-36\u03b3 signaling controls the induced regulatory T cell-Th9 cell balance via NF\u03baB activation and STAT transcription factors","volume":"10","author":"Harusato","year":"2017","journal-title":"Mucosal Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0445","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41385-022-00488-w","article-title":"IL-36 cytokines imprint a colitogenic phenotype on CD4+ T helper cells","volume":"15","author":"Leon","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114349","article-title":"Interleukin-36\u03b2 inhibits CD4+CD25+ regulatory T cells by activating endoplasmic reticulum-phagy in septic mice","volume":"151","author":"Ge","year":"2025","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0455","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0460","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40259-023-00587-5","article-title":"Targeting IL-36 in Inflammatory Skin Diseases","volume":"37","author":"Fukaura","year":"2023","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0465","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14728222.2022.2084381","article-title":"IL-36: a therapeutic target for ulcerative colitis?","volume":"26","author":"Hernandez Santana","year":"2022","journal-title":"Expert Opin Ther Targets."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0470","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/iub.2568","article-title":"Roles of IL-1 and IL-10 family cytokines in the progression of systemic lupus erythematosus: Friends or foes?","volume":"74","author":"Wu","year":"2022","journal-title":"IUBMB Life."},{"key":"10.1016\/j.cyto.2026.157194_bb0475","doi-asserted-by":"crossref","first-page":"1642116","DOI":"10.3389\/fimmu.2025.1642116","article-title":"Dichotomous roles of IL-36 and IL-38 in cardiovascular disease","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb0480","article-title":"The Role of IL-36 in Infectious Diseases: Potential Target for COVID-19?","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb0485","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/annrheumdis-2012-202264","article-title":"The novel cytokine interleukin-36\u03b1 is expressed in psoriatic and rheumatoid arthritis synovium","volume":"72","author":"Frey","year":"2013","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0495","first-page":"31","article-title":"Detection of the novel IL-1 family cytokines by QAH-IL1F-1 assay in rheumatoid arthritis","volume":"62","author":"Wang","year":"2016","journal-title":"Cell Mol Biol (Noisy-le-grand)."},{"key":"10.1016\/j.cyto.2026.157194_bb0500","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.intimp.2018.03.011","article-title":"Increased serum IL-36\u03b1 and IL-36\u03b3 levels in patients with systemic lupus erythematosus: Association with disease activity and arthritis","volume":"58","author":"Mai","year":"2018","journal-title":"Int Immunopharmacol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0490","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36\u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn\u2019s disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb0505","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7933453","article-title":"IL-38 and IL-36 Target Autophagy for Regulating Synoviocyte Proliferation, Migration, and Invasion in Rheumatoid Arthritis","volume":"2021","author":"Hao","year":"2021","journal-title":"Dis Markers."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0510","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/ar4192","article-title":"The severity of experimental arthritis is independent of IL-36 receptor signaling","volume":"15","author":"Lamacchia","year":"2013","journal-title":"Arthritis Res Ther."},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101954","article-title":"Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis","volume":"9","author":"Derer","year":"2014","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0520","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar1946","article-title":"The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes","volume":"8","author":"Magne","year":"2006","journal-title":"Arthritis Res Ther."},{"issue":"491","key":"10.1016\/j.cyto.2026.157194_bb0525","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2585","article-title":"TGF-\u03b2 type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0530","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1021\/acsbiomaterials.2c01144","article-title":"Injectable Temperature-Sensitive Hydrogel Loaded with IL-36Ra for the Relief of Osteoarthritis","volume":"9","author":"Yi","year":"2023","journal-title":"ACS Biomater Sci Eng."},{"key":"10.1016\/j.cyto.2026.157194_bb0535","doi-asserted-by":"crossref","first-page":"16674","DOI":"10.1038\/srep16674","article-title":"IL-36\u03b1: a novel cytokine involved in the catabolic and inflammatory response in chondrocytes","volume":"5","author":"Conde","year":"2015","journal-title":"Sci Rep."},{"key":"10.1016\/j.cyto.2026.157194_bb0540","article-title":"Aged skin exacerbates experimental osteoarthritis via enhanced IL-36R signaling","author":"Chen","year":"2026","journal-title":"Nat Commun."},{"key":"10.1016\/j.cyto.2026.157194_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156117","article-title":"A novel signature of interleukins 36\u03b1, 37, 38, 39 and 40 in ankylosing spondylitis","volume":"162","author":"Jaber","year":"2023","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb0550","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s11010-023-04855-4","article-title":"Elevated serum IL-36\u03b3 levels in patients with ankylosing spondylitis and its association with disease activity","volume":"479","author":"Shi","year":"2024","journal-title":"Mol Cell Biochem."},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb0555","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.cyto.2026.157194_bb0560","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Effisayil 1 Trial Investigators. Trial of Spesolimab for Generalized Pustular Psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0565","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/bjd\/ljad083","article-title":"Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial","volume":"189","author":"Warren","year":"2023","journal-title":"Br J Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0570","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small Molecule IL-36\u03b3 Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis","volume":"9","author":"Todorovi\u0107","year":"2019","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0575","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41467-025-56601-7","article-title":"Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologies","volume":"16","author":"Velcicky","year":"2025","journal-title":"Nat Commun."},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114099","article-title":"Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling","volume":"43","author":"Fields","year":"2024","journal-title":"Cell Rep."},{"issue":"411","key":"10.1016\/j.cyto.2026.157194_bb0585","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.cyto.2026.157194_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117607","article-title":"Discovery of a novel selective small molecule interleukin-36 receptor antagonist for inflammation and cancer","volume":"245","author":"Khan","year":"2026","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.cyto.2026.157194_bb0595","article-title":"IL-12 family cytokines and autoimmune diseases: A potential therapeutic target?","volume":"10","author":"Cui","year":"2024","journal-title":"J Transl Autoimmun."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0600","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/eji.201546095","article-title":"A novel IL-23p19\/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice","volume":"46","author":"Wang","year":"2016","journal-title":"Eur J Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0605","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00011-019-01235-x","article-title":"The IL-23p19\/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man","volume":"68","author":"Bridgewood","year":"2019","journal-title":"Inflamm Res."},{"issue":"18","key":"10.1016\/j.cyto.2026.157194_bb0610","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.2147\/JIR.S488017","article-title":"Interleukin -39 Expression in Pleural Effusion and Its Diagnostic Value for Tuberculous Pleurisy","volume":"5","author":"Song","year":"2025","journal-title":"J Inflamm Res."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0615","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm-2016-0361","article-title":"Elevated serum IL-39 in patients with ST-segment elevation myocardial infarction was related with left ventricular systolic dysfunction","volume":"11","author":"Luo","year":"2017","journal-title":"Biomark Med."},{"key":"10.1016\/j.cyto.2026.157194_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102430","article-title":"Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity","volume":"46","author":"Yang","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"10.1016\/j.cyto.2026.157194_bb0625","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1007\/s00784-022-04681-w","article-title":"Evaluation of IL-23p19\/Ebi3 (IL-39) gingival crevicular fluid levels in periodontal health, gingivitis, and periodontitis","volume":"26","author":"Sari","year":"2022","journal-title":"Clin Oral Investig."},{"key":"10.1016\/j.cyto.2026.157194_bb0630","doi-asserted-by":"crossref","DOI":"10.1186\/s12903-026-07653-8","article-title":"Impact of smoking and periodontitis on salivary IL-39, IL-41, IL-1\u03b2, and TNF-\u03b1 levels: a cross-sectional analysis","author":"Babayi\u011fit","year":"2026","journal-title":"BMC Oral Health."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0635","first-page":"45","article-title":"Detection of serum and tissue levels of interleukin 39 in psoriasis: a case control study","volume":"34","author":"Hassan","year":"2025","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat."},{"issue":"12","key":"10.1016\/j.cyto.2026.157194_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242329","article-title":"Lack of evidence for expression and function of IL-39 in human immune cells","volume":"15","author":"Ecoeur","year":"2020","journal-title":"PLoS One."},{"key":"10.1016\/j.cyto.2026.157194_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2023.110616","article-title":"Circulating interleukin-39 as a potential biomarker for rheumatoid arthritis diagnosis","volume":"119","author":"Ying","year":"2023","journal-title":"Clin Biochem."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0650","first-page":"1660","article-title":"Anti-IL-39 (IL-23p19\/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupus-like mice","volume":"17","author":"Wang","year":"2018","journal-title":"Mol Med Rep."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0655","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.cyto.2026.157194_bb0660","doi-asserted-by":"crossref","unstructured":"Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Pan\u00e9s J, Danese S, Hisamatsu T, Terry NA, Salese L, Van Rampelbergh R, Sahoo A, Vetter ML, Yee J, Han C, Frustaci ME, Wan KYY, Yang Z, Johanns J, Andrews JM, D'Haens GR, Sands BE; GALAXI 2 & 3 Study Group. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet. 2025;406(10501):358-375. doi:https:\/\/doi.org\/10.1016\/S0140-6736(25)00681-6.","DOI":"10.1016\/S0140-6736(25)00681-6"},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb0665","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/14740338.2023.2223956","article-title":"Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"22","author":"Xiang","year":"2023","journal-title":"Expert Opin Drug Saf."},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb0670","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.4049\/jimmunol.1700534","article-title":"Identification of IL-40, a Novel B Cell-Associated Cytokine","volume":"199","author":"Catalan-Dibene","year":"2017","journal-title":"J Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0675","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002894","article-title":"New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis","volume":"9","author":"Navr\u00e1tilov\u00e1","year":"2023","journal-title":"RMD Open."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0680","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-025-05257-2","article-title":"Inhibition of Interleukin-40 prevents multi-organ damage during sepsis by blocking NETosis","volume":"29","author":"Cai","year":"2025","journal-title":"Crit Care."},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0685","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321578","article-title":"Increased serum levels of IL-40 are associated with IgA and NETosis biomarkers in Covid-19 patients: IL-40 and infectious diseases","volume":"20","author":"Bagriacik","year":"2025","journal-title":"PLoS One."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0690","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13075-024-03372-z","article-title":"IL-40 is up-regulated in the synovial fluid and cartilage of osteoarthritis patients and contributes to the alteration of chondrocytes phenotype in vitro","volume":"26","author":"Cerezo","year":"2024","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0695","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002738","article-title":"Possible role for IL-40 and IL-40-producing cells in the lymphocytic infiltrated salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Guggino","year":"2023","journal-title":"RMD Open."},{"key":"10.1016\/j.cyto.2026.157194_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745523","article-title":"IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis","volume":"12","author":"Navr\u00e1tilov\u00e1","year":"2021","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0705","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/09612033251361037","article-title":"Potential involvement of IL-40 in kidney disease associated to systemic lupus erythematosus","volume":"34","author":"Rizzo","year":"2025","journal-title":"Lupus"},{"key":"10.1016\/j.cyto.2026.157194_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1680530","article-title":"Serum interleukin-40 increases in anti-AchR antibody-positive myasthenia gravis and correlates with disease activity","volume":"16","author":"Jia","year":"2025","journal-title":"Front Neurol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0715","doi-asserted-by":"crossref","first-page":"28945","DOI":"10.1038\/s41598-024-80104-y","article-title":"Serum IL-40 increases in patients with rheumatoid arthritis and correlates with some clinical characteristics and comorbidities","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0720","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/eji.200737810","article-title":"IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells","volume":"37","author":"Niedbala","year":"2007","journal-title":"Eur J Immunol."},{"issue":"7169","key":"10.1016\/j.cyto.2026.157194_bb0725","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb0730","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0735","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2227","article-title":"The composition and signaling of the IL-35 receptor are unconventional","volume":"13","author":"Collison","year":"2012","journal-title":"Nat Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0740","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The Immunobiology of the Interleukin-12 Family: Room for Discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0745","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med."},{"issue":"7492","key":"10.1016\/j.cyto.2026.157194_bb0750","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.cyto.2026.157194_bb0755","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat Immunol."},{"issue":"45","key":"10.1016\/j.cyto.2026.157194_bb0760","doi-asserted-by":"crossref","first-page":"73003","DOI":"10.18632\/oncotarget.12193","article-title":"Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1\/STAT3","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cyto.2026.157194_bb0765","article-title":"Systematic Review of Interleukin-35 in Endothelial Dysfunction: A New Target for Therapeutic Intervention","author":"Li","year":"2025","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cyto.2026.157194_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108729","article-title":"Overexpression of ascitic interleukin-35 induces CD8+ T cell exhaustion in liver cirrhotic patients with spontaneous bacterial peritonitis","volume":"108","author":"Yang","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.cyto.2026.157194_bb0775","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3389\/fimmu.2019.01032","article-title":"Interleukin-35 Dampens CD8+ T Cells Activity in Patients With Non-viral Hepatitis-Related Hepatocellular Carcinoma","volume":"10","author":"Yang","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb0780","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3389\/fimmu.2018.01417","article-title":"Interleukin-35 Inhibits TNF-\u03b1-Induced Osteoclastogenesis and Promotes Apoptosis via Shifting the Activation From TNF Receptor-Associated Death Domain (TRADD)-TRAF2 to TRADD-Fas-Associated Death Domain by JAK1\/STAT1","volume":"9","author":"Peng","year":"2018","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb0785","first-page":"820","article-title":"IL-35 prevent bone loss through promotion of bone formation and angiogenesis in rheumatoid arthritis","volume":"37","author":"Liu","year":"2019","journal-title":"Clin Exp Rheumatol."},{"issue":"7","key":"10.1016\/j.cyto.2026.157194_bb0790","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.autrev.2018.01.017","article-title":"Emerging role of IL-35 in inflammatory autoimmune diseases","volume":"17","author":"Su","year":"2018","journal-title":"Autoimmun Rev."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0795","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/1535-7163.MCT-23-0242","article-title":"IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment","volume":"23","author":"Yi","year":"2024","journal-title":"Mol Cancer Ther."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0800","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12026-018-8998-3","article-title":"IL-35: a new immunomodulator in autoimmune rheumatic diseases","volume":"66","author":"Sakkas","year":"2018","journal-title":"Immunol Res."},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb0805","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11033-016-4034-7","article-title":"Interleukin-35 (IL-35) inhibits proliferation and promotes apoptosis of fibroblast-like synoviocytes isolated from mice with collagen-induced arthritis","volume":"43","author":"Li","year":"2016","journal-title":"Mol Biol Rep."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0810","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00198-015-3410-9","article-title":"Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes","volume":"27","author":"Li","year":"2016","journal-title":"Osteoporos Int."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0815","first-page":"223","article-title":"Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes","volume":"36","author":"Wu","year":"2018","journal-title":"Clin Exp Rheumatol."},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb0820","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/keu528","article-title":"Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis","volume":"54","author":"Nakano","year":"2015","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0825","doi-asserted-by":"crossref","first-page":"2565438","DOI":"10.1080\/07853890.2025.2565438","article-title":"iTr35 cells: a novel immunoregulatory subset involved in bone loss in rheumatoid arthritis and clinical implications","volume":"57","author":"Li","year":"2025","journal-title":"Ann Med."},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb0830","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.injury.2010.11.017","article-title":"TRACP 5b and CTX as osteological markers of delayed fracture healing","volume":"42","author":"Moghaddam","year":"2011","journal-title":"Injury"},{"issue":"7","key":"10.1016\/j.cyto.2026.157194_bb0835","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132674","article-title":"Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis","volume":"10","author":"\u0160enolt","year":"2015","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb0840","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jim-2018-000814","article-title":"Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity","volume":"67","author":"Li","year":"2019","journal-title":"J Investig Med."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0845","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1620\/tjem.237.77","article-title":"Low Serum Levels of Interleukin 35 in Patients with Rheumatoid Arthritis","volume":"237","author":"Ning","year":"2015","journal-title":"Tohoku J Exp Med."},{"key":"10.1016\/j.cyto.2026.157194_bb0850","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.655114","article-title":"Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis","volume":"12","author":"Xin","year":"2021","journal-title":"Front Pharmacol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0855","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cyto.2015.01.019","article-title":"Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis","volume":"73","author":"Filkov\u00e1","year":"2015","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb0870","first-page":"5366","article-title":"Decreased regulatory T-cell frequency and interleukin-35 levels in patients with rheumatoid arthritis","volume":"16","author":"Zhang","year":"2018","journal-title":"Exp Ther Med."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0875","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s10753-022-01749-3","article-title":"Interleukin-35 Promote Osteogenesis and Inhibit Adipogenesis: Role of Wnt\/\u03b2-Catenin and PPAR\u03b3 Signaling Pathways","volume":"46","author":"Li","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.cyto.2026.157194_bb0880","article-title":"Interleukin-35 Is Involved in Angiogenesis\/Bone Remodeling Coupling Through T Helper 17\/Interleukin-17 Axis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0865","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5114\/ceji.2018.77384","article-title":"IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-\u03baB ligand","volume":"43","author":"Yago","year":"2018","journal-title":"Cent Eur J Immunol."},{"issue":"14","key":"10.1016\/j.cyto.2026.157194_bb0885","doi-asserted-by":"crossref","first-page":"10308","DOI":"10.1074\/jbc.275.14.10308","article-title":"Identification and initial characterization of four novel members of the interleukin-1 family","volume":"275","author":"Kumar","year":"2000","journal-title":"J Biol Chem."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0890","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/geno.2000.6184","article-title":"Identification and gene organization of three novel members of the IL-1 family on human chromosome 2","volume":"66","author":"Busfield","year":"2000","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/cyto.2000.0799","article-title":"IL-1H, an interleukin 1-related protein that binds IL-18 receptor\/IL-1Rrp","volume":"13","author":"Pan","year":"2001","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0900","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2026.157194_bb0905","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3058640","article-title":"Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases","volume":"2018","author":"Jia","year":"2018","journal-title":"Biomed Res Int."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0910","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol Rev."},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb0915","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/1389450121666200429114926","article-title":"IL-37 As a Potential Biotherapeutics of Inflammatory Diseases","volume":"21","author":"Bai","year":"2020","journal-title":"Curr Drug Targets."},{"key":"10.1016\/j.cyto.2026.157194_bb0920","doi-asserted-by":"crossref","first-page":"1278521","DOI":"10.3389\/fimmu.2023.1278521","article-title":"Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process","volume":"14","author":"Gu","year":"2023","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb0925","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cyto.2015.04.009","article-title":"Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease","volume":"75","author":"Fonseca-Camarillo","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2026.157194_bb0930","doi-asserted-by":"crossref","first-page":"14478","DOI":"10.1038\/srep14478","article-title":"Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells","volume":"5","author":"Shuai","year":"2015","journal-title":"Sci Rep."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0935","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1189\/jlb.3MA0616-287R","article-title":"Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells","volume":"101","author":"Rudloff","year":"2017","journal-title":"J Leukoc Biol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0940","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2604877","article-title":"IL-37\/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells","volume":"15","author":"Landolina","year":"2026","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb0945","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1073\/pnas.1821111116","article-title":"Role for nuclear interleukin-37 in the suppression of innate immunity","volume":"116","author":"Li","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"15","key":"10.1016\/j.cyto.2026.157194_bb0950","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.3390\/ijms20153701","article-title":"Mast Cells May Regulate The Anti-Inflammatory Activity of IL-37","volume":"20","author":"Theoharides","year":"2019","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.cyto.2026.157194_bb0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2021.09.004","article-title":"The interleukin-1 cytokine family members: Role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy","volume":"62","author":"Boersma","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb0960","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni.3103","article-title":"IL-37 requires the receptors IL-18R\u03b1 and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction","volume":"16","author":"Nold-Petry","year":"2015","journal-title":"Nat Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109705","article-title":"The role of IL-37 in skin and connective tissue diseases","volume":"122","author":"Pan","year":"2020","journal-title":"Biomed Pharmacother."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb0970","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1515\/hsz-2018-0254","article-title":"IL-37 affects the occurrence and development of endometriosis by regulating the biological behavior of endometrial stromal cells through multiple signaling pathways","volume":"399","author":"Jiang","year":"2018","journal-title":"Biol Chem."},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb0975","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41419-019-1904-7","article-title":"Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K\/AKT signaling pathway","volume":"10","author":"Ye","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2026.157194_bb0980","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.3389\/fmicb.2019.02482","article-title":"Interleukin-37 Ameliorates Influenza Pneumonia by Attenuating Macrophage Cytokine Production in a MAPK-Dependent Manner","volume":"10","author":"Qi","year":"2019","journal-title":"Front Microbiol."},{"key":"10.1016\/j.cyto.2026.157194_bb0985","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3389\/fimmu.2020.00752","article-title":"IL-37 Ameliorating Allergic Inflammation in Atopic Dermatitis Through Regulating Microbiota and AMPK-mTOR Signaling Pathway-Modulated Autophagy Mechanism","volume":"11","author":"Hou","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0990","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190314","article-title":"Inflammasome signaling and regulation of interleukin-1 family cytokines","volume":"217","author":"Chan","year":"2020","journal-title":"J Exp Med."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb0995","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/cells9010178","article-title":"Parsing the IL-37-Mediated Suppression of Inflammasome Function","volume":"9","author":"Rudloff","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb1000","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.1944","article-title":"IL-37 is a fundamental inhibitor of innate immunity","volume":"11","author":"Nold","year":"2010","journal-title":"Nat Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb1005","first-page":"561","article-title":"Evolution of interleukin-18 binding proteins and interleukin-1 receptor, type II proteins","volume":"15","author":"Watanabe","year":"2005","journal-title":"Int J Mol Med."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb1010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/imr.12606","article-title":"The family of the interleukin-1 receptors","volume":"281","author":"Boraschi","year":"2018","journal-title":"Immunol Rev."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb1015","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4049\/jimmunol.170.4.2100","article-title":"Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein","volume":"170","author":"Banda","year":"2003","journal-title":"J Immunol."},{"issue":"37","key":"10.1016\/j.cyto.2026.157194_bb1020","doi-asserted-by":"crossref","first-page":"14224","DOI":"10.1074\/jbc.RA118.003698","article-title":"Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue","volume":"293","author":"Ballak","year":"2018","journal-title":"J Biol Chem."},{"key":"10.1016\/j.cyto.2026.157194_bb1025","doi-asserted-by":"crossref","unstructured":"Ellisdon AM, Nold-Petry CA, D'Andrea L, Cho SX, Lao JC, Rudloff I, Ngo D, Lo CY, Soares da Costa TP, Perugini MA, Conroy PJ, Whisstock JC, Nold MF. Homodimerization attenuates the anti-inflammatory activity of interleukin-37. Sci Immunol. 2017;2(8):eaaj1548. doi: https:\/\/doi.org\/10.1126\/sciimmunol.aaj1548.","DOI":"10.1126\/sciimmunol.aaj1548"},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb1030","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13309","article-title":"Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds","volume":"20","author":"Hamilton","year":"2021","journal-title":"Aging Cell."},{"key":"10.1016\/j.cyto.2026.157194_bb1035","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2147\/IJGM.S309436","article-title":"Correlation Between Level of Interleukin-37 and Rheumatoid Arthritis Progression","volume":"14","author":"Zhu","year":"2021","journal-title":"Int J Gen Med."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb1040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/1756-185X.13539","article-title":"Elevated expression of interleukin-37 in patients with rheumatoid arthritis","volume":"22","author":"Yuan","year":"2019","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.cyto.2026.157194_bb1045","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fmed.2018.00364","article-title":"IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels","volume":"5","author":"Robert","year":"2019","journal-title":"Front Med (Lausanne)."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb1050","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.4049\/jimmunol.1401810","article-title":"IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17-Triggering Cytokine Production and Limiting Th17 Cell Proliferation","volume":"194","author":"Ye","year":"2015","journal-title":"J Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157194_bb1055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095346","article-title":"Plasma levels of IL-37 and correlation with TNF-\u03b1, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152382","article-title":"IL-37 alleviates TNF-\u03b1-induced pyroptosis of rheumatoid arthritis fibroblast-like synoviocytes by inhibiting the NF-\u03baB\/GSDMD signaling pathway","volume":"228","author":"Ren","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.cyto.2026.157194_bb1065","doi-asserted-by":"crossref","first-page":"1629759","DOI":"10.3389\/fimmu.2025.1629759","article-title":"The role of IL-37 and IL-38 in rheumatoid arthritis, the potential clinical applications in precision medicine","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101968","article-title":"Genetics of rheumatoid arthritis","volume":"38","author":"Sharma","year":"2024","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb1075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.joca.2018.08.016","article-title":"IL-37 diminishes proteoglycan loss in human OA cartilage: donor-specific link between IL-37 and MMP-3","volume":"27","author":"van Geffen","year":"2019","journal-title":"Osteoarthritis Cartilage."},{"key":"10.1016\/j.cyto.2026.157194_bb1080","article-title":"Interleukin-37 Ameliorates Articular Cartilage Damage in Two Murine Models of Osteoarthritis","author":"van Geffen","year":"2025","journal-title":"Cartilage"},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb1085","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12692","article-title":"IL-37b alleviates inflammation in the temporomandibular joint cartilage via IL-1R8 pathway","volume":"52","author":"Luo","year":"2019","journal-title":"Cell Prolif."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb1090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.joca.2020.11.006","article-title":"Senolytic agent Quercetin ameliorates intervertebral disc degeneration via the Nrf2\/NF-\u03baB axis","volume":"29","author":"Shao","year":"2021","journal-title":"Osteoarthritis Cartilage."},{"key":"10.1016\/j.cyto.2026.157194_bb1095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.matbio.2019.02.004","article-title":"p16Ink4a deletion in cells of the intervertebral disc affects their matrix homeostasis and senescence associated secretory phenotype without altering onset of senescence","volume":"82","author":"Novais","year":"2019","journal-title":"Matrix Biol."},{"issue":"44","key":"10.1016\/j.cyto.2026.157194_bb1100","doi-asserted-by":"crossref","first-page":"38408","DOI":"10.1021\/acsnano.5c11287","article-title":"On-Demand Collaborative Delivery for Remodeling the Senescent Microenvironment in Intervertebral Disc Degeneration","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb1105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12967-021-02830-5","article-title":"Deregulation of IL-37 and its miRNAs modulators in sarcopenic patients after rehabilitation","volume":"19","author":"La Rosa","year":"2021","journal-title":"J Transl Med."},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb1110","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1089\/107999001753289505","article-title":"Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14","volume":"21","author":"Bensen","year":"2001","journal-title":"J Interferon Cytokine Res."},{"issue":"23","key":"10.1016\/j.cyto.2026.157194_bb1115","doi-asserted-by":"crossref","first-page":"20597","DOI":"10.1074\/jbc.M010095200","article-title":"Cloning and characterization of IL-1HY2, a novel interleukin-1 family member","volume":"276","author":"Lin","year":"2001","journal-title":"J Biol Chem."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb1120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.12612","article-title":"Biology of IL-38 and its role in disease","volume":"281","author":"van de Veerdonk","year":"2018","journal-title":"Immunol Rev."},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb1125","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.991","article-title":"The emerging role of IL-38 in diseases: A comprehensive review","volume":"11","author":"Chen","year":"2023","journal-title":"Immun Inflamm Dis."},{"issue":"13","key":"10.1016\/j.cyto.2026.157194_bb1130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41388-025-03293-4","article-title":"The complex roles of IL-36 and IL-38 in cancer: friends or foes?","volume":"44","author":"Finucane","year":"2025","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb1135","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14550","article-title":"Emerging functions and therapeutic targets of IL-38 in central nervous system diseases","volume":"30","author":"Gao","year":"2024","journal-title":"CNS Neurosci Ther."},{"key":"10.1016\/j.cyto.2026.157194_bb1140","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3389\/fimmu.2018.01462","article-title":"Role of Interleukin-38 in Chronic Inflammatory Diseases: A Comprehensive Review","volume":"9","author":"Xu","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107528","article-title":"Biology of interleukin-38 and its role in chronic inflammatory diseases","volume":"95","author":"Xia","year":"2021","journal-title":"Int Immunopharmacol."},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb1150","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/biom9080345","article-title":"IL-38: A New Player in Inflammatory Autoimmune Disorders","volume":"9","author":"Xie","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.cyto.2026.157194_bb1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155808","article-title":"Multifaceted roles of IL-38 in inflammation and cancer","volume":"151","author":"Diaz-Barreiro","year":"2022","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb1160","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/jcmm.14902","article-title":"Interleukin-38 protects against sepsis by augmenting immunosuppressive activity of CD4+ CD25+ regulatory T cells","volume":"24","author":"Ge","year":"2020","journal-title":"J Cell Mol Med."},{"key":"10.1016\/j.cyto.2026.157194_bb1165","article-title":"Effects of IL-38 on Macrophages and Myocardial Ischemic Injury","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117738","article-title":"Interleukin-38-overexpressing adenovirus infection in dendritic cell-based treatment enhances immunotherapy for allergic asthma via inducing Foxp3+ regulatory T cells","volume":"181","author":"Chuang","year":"2024","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.cyto.2026.157194_bb1175","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3389\/fimmu.2018.01462","article-title":"Role of Interleukin-38 in Chronic Inflammatory Diseases: A Comprehensive Review","volume":"9","author":"Xu","year":"2018","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb1180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40744-024-00640-x","article-title":"Emerging Role of Interleukin-38 (IL-38) in the Development of Rheumatoid Arthritis","volume":"11","author":"Liang","year":"2024","journal-title":"Rheumatol Ther."},{"issue":"7","key":"10.1016\/j.cyto.2026.157194_bb1185","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/annrheumdis-2016-210630","article-title":"IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro","volume":"76","author":"Boutet","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.cyto.2026.157194_bb1190","first-page":"386","article-title":"IL-38: A new factor in rheumatoid arthritis","volume":"4","author":"Takenaka","year":"2015","journal-title":"Biochem Biophys Rep."},{"key":"10.1016\/j.cyto.2026.157194_bb1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107489","article-title":"The elevated expression of IL-38 serves as an anti-inflammatory factor in osteoarthritis and its protective effect in osteoarthritic chondrocytes","volume":"94","author":"Jiang","year":"2021","journal-title":"Int Immunopharmacol."},{"issue":"8","key":"10.1016\/j.cyto.2026.157194_bb1200","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1302\/2046-3758.118.BJR-2021-0188.R1","article-title":"Long noncoding RNA H19 alleviates inflammation in osteoarthritis through interactions between TP53, IL-38, and IL-36 receptor","volume":"11","author":"Zhou","year":"2022","journal-title":"Bone Joint Res."},{"key":"10.1016\/j.cyto.2026.157194_bb1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150158","article-title":"Interleukin 38 improves insulin resistance in hyperlipidemic skeletal muscle cells via PPAR\u03b4\/SIRT1-mediated suppression of STAT3 signaling and oxidative stress","volume":"722","author":"Sun","year":"2024","journal-title":"Biochem Biophys Res Commun."},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb1210","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/sj.emboj.7600202","article-title":"Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension","volume":"23","author":"Nishino","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.cyto.2026.157194_bb1215","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108730","article-title":"Metrnl as a secreted protein: Discovery and cardiovascular research","volume":"263","author":"Miao","year":"2024","journal-title":"Pharmacol Ther."},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb1220","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.3390\/ijms26104485","article-title":"Meteorin-\u03b2: A Novel Biomarker and Therapeutic Target on Its Way to the Regulation of Human Diseases","volume":"26","author":"Wang","year":"2025","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.cyto.2026.157194_bb1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.157058","article-title":"Unveiling IL-41: A novel biomarker for polymyositis and dermatomyositis diagnosis","volume":"196","author":"Li","year":"2025","journal-title":"Cytokine"},{"issue":"14","key":"10.1016\/j.cyto.2026.157194_bb1230","doi-asserted-by":"crossref","first-page":"1098570","DOI":"10.3389\/fimmu.2023.1098570","article-title":"Meteorin-like\/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies","volume":"24","author":"Li","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb1235","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12964-024-01767-8","article-title":"Metrnl: a promising biomarker and therapeutic target for cardiovascular and metabolic diseases","volume":"22","author":"Dong","year":"2024","journal-title":"Cell Commun Signal."},{"issue":"12","key":"10.1016\/j.cyto.2026.157194_bb1240","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41401-020-00529-9","article-title":"Involvement of the secreted protein Metrnl in human diseases","volume":"41","author":"Miao","year":"2020","journal-title":"Acta Pharmacol Sin."},{"issue":"4","key":"10.1016\/j.cyto.2026.157194_bb1245","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cns.12219","article-title":"Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression","volume":"20","author":"Li","year":"2014","journal-title":"CNS Neurosci Ther."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb1250","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cell.2014.03.065","article-title":"Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis","volume":"157","author":"Rao","year":"2014","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb1255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0147-5","article-title":"METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPAR\u03b4-dependent pathways in skeletal muscle of mice","volume":"50","author":"Jung","year":"2018","journal-title":"Exp Mol Med."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb1260","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.advms.2021.01.007","article-title":"Meteorin-like protein (METRNL)\/IL-41 improves LPS-induced inflammatory responses via AMPK or PPAR\u03b4-mediated signaling pathways","volume":"66","author":"Jung","year":"2021","journal-title":"Adv Med Sci."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb1265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2014.11.006","article-title":"METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages","volume":"156","author":"Ushach","year":"2015","journal-title":"Clin Immunol."},{"issue":"6599","key":"10.1016\/j.cyto.2026.157194_bb1270","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.abn3027","article-title":"Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase","volume":"376","author":"Reboll","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb1275","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1038\/s41467-022-35390-3","article-title":"Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro\/adipogenic progenitor signaling","volume":"13","author":"Lee","year":"2022","journal-title":"Nat Commun."},{"key":"10.1016\/j.cyto.2026.157194_bb1280","doi-asserted-by":"crossref","first-page":"6283932","DOI":"10.1155\/2018\/6283932","article-title":"Aerobic Exercise Increases Meteorin-Like Protein in Muscle and Adipose Tissue of Chronic High-Fat Diet-Induced Obese Mice","volume":"2018","author":"Bae","year":"2018","journal-title":"Biomed Res Int."},{"issue":"9","key":"10.1016\/j.cyto.2026.157194_bb1285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0147-5","article-title":"METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPAR\u03b4-dependent pathways in skeletal muscle of mice","volume":"50","author":"Jung","year":"2018","journal-title":"Exp Mol Med."},{"key":"10.1016\/j.cyto.2026.157194_bb1290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mito.2023.07.003","article-title":"Mitochondrial dysfunction and skeletal muscle atrophy: Causes, mechanisms, and treatment strategies","volume":"72","author":"Kubat","year":"2023","journal-title":"Mitochondrion"},{"key":"10.1016\/j.cyto.2026.157194_bb1295","doi-asserted-by":"crossref","first-page":"1452696","DOI":"10.1155\/2020\/1452696","article-title":"PGC-1\u03b1, Inflammation, and Oxidative Stress: An Integrative View in Metabolism","volume":"2020","author":"Rius-P\u00e9rez","year":"2020","journal-title":"Oxid Med Cell Longev."},{"issue":"3","key":"10.1016\/j.cyto.2026.157194_bb1300","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s42255-020-0184-y","article-title":"Meteorin-like facilitates skeletal muscle repair through a Stat3\/IGF-1 mechanism","volume":"2","author":"Baht","year":"2020","journal-title":"Nat Metab."},{"issue":"1","key":"10.1016\/j.cyto.2026.157194_bb1305","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1038\/s41467-022-35390-3","article-title":"Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro\/adipogenic progenitor signaling","volume":"13","author":"Lee","year":"2022","journal-title":"Nat Commun."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb1310","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: a review","volume":"51","author":"Ashton","year":"2021","journal-title":"Intern Med J."},{"key":"10.1016\/j.cyto.2026.157194_bb1315","doi-asserted-by":"crossref","first-page":"1595181","DOI":"10.3389\/fimmu.2025.1595181","article-title":"Metrnl\/Meteorin-like\/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb1320","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114118","article-title":"Exercise induced meteorin-like protects chondrocytes against inflammation and pyroptosis in osteoarthritis by inhibiting PI3K\/Akt\/NF-\u03baB and NLRP3\/caspase-1\/GSDMD signaling","volume":"158","author":"Liu","year":"2023","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.cyto.2026.157194_bb1325","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156026","article-title":"Elevated levels of Metrnl in rheumatoid arthritis: Association with disease activity","volume":"159","author":"Zhang","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2026.157194_bb1330","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cca.2022.11.021","article-title":"Increased serum IL-41 is associated with disease activity in rheumatoid arthritis","volume":"538","author":"Gong","year":"2023","journal-title":"Clin Chim Acta."},{"issue":"13","key":"10.1016\/j.cyto.2026.157194_bb1335","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.7150\/ijms.98752","article-title":"Interleukin 41 As A Potential Predictor of Bio-Therapy Efficacy In Patients With Rheumatoid Arthritis: A Prospective Observational Study","volume":"21","author":"Joci\u0107","year":"2024","journal-title":"Int J Med Sci."},{"key":"10.1016\/j.cyto.2026.157194_bb1340","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108253","article-title":"The novel cytokine Metrnl\/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts","volume":"208","author":"Bridgewood","year":"2019","journal-title":"Clin Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb1345","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.157058","article-title":"Unveiling IL-41: A novel biomarker for polymyositis and dermatomyositis diagnosis","volume":"196","author":"Li","year":"2025","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.cyto.2026.157194_bb1350","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1002\/jor.25286","article-title":"The role of Meteorin-like in skeletal development and bone fracture healing","volume":"40","author":"Huang","year":"2022","journal-title":"J Orthop Res."},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb1355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164446","article-title":"Meteorin-Like Shows Unique Expression Pattern in Bone and Its Overexpression Inhibits Osteoblast Differentiation","volume":"11","author":"Gong","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.cyto.2026.157194_bb1360","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.752892","article-title":"Association Between Factors Involved in Bone Remodeling (Osteoactivin and OPG) With Plasma Levels of Irisin and Meteorin-Like Protein in People With T2D and Obesity","volume":"12","author":"Cherian","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"6","key":"10.1016\/j.cyto.2026.157194_bb1365","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cell.2014.03.065","article-title":"Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis","volume":"157","author":"Rao","year":"2014","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb1370","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41423-021-00803-8","article-title":"Meteorin-\u03b2\/Meteorin like\/IL-41 attenuates airway inflammation in house dust mite-induced allergic asthma","volume":"19","author":"Gao","year":"2022","journal-title":"Cell Mol Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb1375","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/all.16150","article-title":"Meteorin-like protein\/METRNL\/Interleukin-41 ameliorates atopic dermatitis-like inflammation","volume":"80","author":"Huang","year":"2025","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.cyto.2026.157194_bb1380","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.4049\/jimmunol.1800435","article-title":"Meteorin-like\/Meteorin-\u03b2 Is a Novel Immunoregulatory Cytokine Associated with Inflammation","volume":"201","author":"Ushach","year":"2018","journal-title":"J Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb1385","doi-asserted-by":"crossref","DOI":"10.1016\/j.dci.2021.104289","article-title":"Meteorin-like\/Meteorin-\u03b2 upregulates proinflammatory cytokines via NF-\u03baB pathway in grass carp Ctenopharyngodon idella","volume":"127","author":"Wang","year":"2022","journal-title":"Dev Comp Immunol."},{"key":"10.1016\/j.cyto.2026.157194_bb1390","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109690","article-title":"Protective role of the novel cytokine Metrnl\/ interleukin-41 in host immunity defense during sepsis by promoting macrophage recruitment and modulating Treg\/Th17 immune cell balance","volume":"254","author":"Chen","year":"2023","journal-title":"Clin Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157194_bb1395","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3892\/etm.2024.12601","article-title":"Increased serum IL-41 associated with acute exacerbation of chronic obstructive pulmonary disease","volume":"28","author":"Cen","year":"2024","journal-title":"Exp Ther Med."},{"key":"10.1016\/j.cyto.2026.157194_bb1400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.imlet.2023.11.003","article-title":"Interleukin-41 as a biomarker of the anti-inflammatory response associated with hyperuricemia","volume":"264","author":"Zhang","year":"2023","journal-title":"Immunol Lett."},{"issue":"14","key":"10.1016\/j.cyto.2026.157194_bb1405","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/cells13141205","article-title":"The Novel Cytokine Interleukin-41\/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis","volume":"13","author":"Freedman","year":"2024","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.cyto.2026.157194_bb1410","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24676","article-title":"Decreased serum interleukin-41\/Metrnl levels in patients with Graves\u2019 disease","volume":"36","author":"Gong","year":"2022","journal-title":"J Clin Lab Anal."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346662600089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346662600089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:50:26Z","timestamp":1787093426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104346662600089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":280,"alternative-id":["S104346662600089X"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157194","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational perspectives of next-generation cytokine therapies for musculoskeletal disorders","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157194"}}